Design Therapeutics reported second quarter 2026 financial results on August 3, 2026. The company incurred a net loss of $20.2 million and spent $16.4 million on research and development and $5.8 million on general and administrative expenses. Cash, cash equivalents, and investment securities totaled $207.4 million at quarter-end. Clinically, the RESTORE-FA trial for DT-216P2 in Friedreich ataxia is being modified to evaluate a 12-week dosing cohort with data expected in Q1 2027. Dosing has initiated in the Phase 1 MAD trial of DT-818 for myotonic dystrophy type 1, while the DT-168 FECD trial faces delays due to supply issues. Design Therapeutics is a clinical-stage biotechnology company developing gene-targeted small molecule therapies for degenerative genetic diseases.